Apellis Pharmaceuticals And Sobi Announce Positive One-Year Results From Phase 2 NOBLE Study Of Pegcetacoplan For Post-Transplant Recurrence Of C3 Glomerulopathy (C3G) And IC-MPGN

5/24/24 10:01:58 AM ET

$APLS

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $APLS alert in real time by email

Rapid reduction in disease activity seen at 12 weeks was sustained at one year
55% of patients showed zero C3c staining intensity, indicating that C3c deposits were cleared
Highlighted as late-breaking oral presentation at the European Renal Association (ERA) Congress

Get the next $APLS alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$APLS

Date	Price Target	Rating	Analyst
11/21/2024	$31.00	Equal-Weight	Morgan Stanley
10/25/2024	$25.00	Sector Perform	RBC Capital Mkts
10/16/2024		Sector Outperform	Scotiabank
10/16/2024		Outperform	William Blair
5/31/2024	$46.00	Neutral	Piper Sandler
2/5/2024	$68.00 → $80.00	Hold → Buy	Jefferies
12/14/2023		Overweight → Equal Weight	Wells Fargo
11/9/2023	$74.00	Buy	Goldman

More analyst ratings

$APLS
Leadership Updates

Live Leadership Updates

Apellis Appoints Leading Expert Dr. Philip Ferrone as Chief Medical Retina Advisor
WALTHAM, Mass., March 11, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) today announced that leading retina specialist Philip Ferrone, M.D., will join the company as Chief Medical Retina Advisor, effective March 18. "Phil is globally renowned for his leadership in retina, including as a past president of the American Society of Retina Specialists (ASRS), so we are delighted to welcome him to the Apellis team," said Caroline Baumal, M.D., Chief Medical Officer, Apellis. "Phil has extensive expertise in retina research and patient care, which will be invaluable as we continue to bring SYFOVRE to patients with GA and advance our retina pipeline." "It is an honor to jo
3/11/24 7:00:00 AM ET
$APLS
Biotechnology: Pharmaceutical Preparations
Health Care
Apellis Appoints Leading Retina Specialist Dr. Caroline Baumal as Chief Medical Officer
WALTHAM, Mass., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), a global biopharmaceutical company and leader in complement, today announced that leading retina specialist Caroline Baumal, M.D., has joined Apellis as chief medical officer. Dr. Baumal replaces Federico Grossi, M.D., Ph.D., who plans to remain at Apellis until February 28, 2023 to help with the transition and preparations for the potential launch of pegcetacoplan for geographic atrophy (GA). "Caroline is a world-renowned retina specialist who has been at the forefront of retina research and patient care for over 25 years, and we are thrilled to welcome her to Apellis," said Cedric Francois, M.
1/5/23 7:00:00 AM ET
$APLS
Biotechnology: Pharmaceutical Preparations
Health Care
Cognito Therapeutics Appoints Gerald Chan as Chairman of the Board
Cognito Therapeutics, a Phase 3-ready disease-modifying digital therapeutics company, today announced the appointment of Gerald Chan, ScD. as Chairman of the Board. Cognito is a pioneer in using neuromodulation to engage novel targets of neuronal pathophysiology to achieve disease modification in neurodegenerative diseases. Dr. Chan is the co-founder of Morningside, a privately held venture capital and private equity firm. Since inception, Morningside has focused on the development and commercialization of novel scientific discoveries in both the life sciences and technology sectors. "The use of non-pharmacological interventions to treat neurocognitive decline represents a fundamental shif
7/6/21 8:00:00 AM ET
$MITO
$APLS
Biotechnology: Pharmaceutical Preparations
Health Care

$APLS
Financials

Live finance-specific insights

Apellis Pharmaceuticals Reports Third Quarter 2024 Financial Results
Generated $196.8 million in 3Q 2024 revenues, including $176.6 million in U.S. net product salesGrew SYFOVRE® (pegcetacoplan injection) demand by 7% quarter-over-quarter, with U.S. net product revenue of $152.0 million Increase in demand offset by higher gross-to-net adjustments in the quarter Following FDA feedback, on track to file an sNDA seeking approval of pegcetacoplan for C3G / primary IC-MPGN in early 2025 based on positive 6-month Phase 3 VALIANT results Cash and cash equivalents of $396.9 million as of September 30, 2024; projected revenues and cash expected to be sufficient to fund operations to positive cash flow Management to host conference call today at 8:30 a.m. ET
11/5/24 7:05:00 AM ET
$APLS
Biotechnology: Pharmaceutical Preparations
Health Care
Apellis Pharmaceuticals to Host Conference Call on November 5, 2024, to Discuss Third Quarter 2024 Financial Results
WALTHAM, Mass., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) today announced that the company will host a conference call and webcast to discuss its third quarter 2024 financial results on Tuesday, November 5, 2024, at 8:30 a.m. ET. To access the live call by phone, please pre-register for the call here. A live audio webcast of the event and accompanying slides may also be accessed through the "Events and Presentations" page of the "Investors and Media" section of the company's website. A replay of the webcast will be available for 90 days following the event. About Apellis Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that combines
10/22/24 7:00:00 AM ET
$APLS
Biotechnology: Pharmaceutical Preparations
Health Care
Apellis and Sobi Announce Positive Topline Results from Phase 3 VALIANT Study of Pegcetacoplan in C3G and Primary IC-MPGN
Met the primary endpoint, achieving statistically significant 68% (p<0.0001) reduction in proteinuria compared to placebo in a broad study populationPositive results consistent across all subgroups, including C3G and IC-MPGN, adolescent and adult patients, and native and post-transplant kidneysDemonstrated favorable safety, consistent with established profileCompanies plan to submit data for regulatory approval in the US and EU Apellis to host a conference call today at 8:00 a.m. ET WALTHAM, Mass. and STOCKHOLM, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) and Sobi® (STO: SOBI) today announced positive topline results from the Phase 3 VALIANT study investi
8/8/24 7:00:00 AM ET
$APLS
Biotechnology: Pharmaceutical Preparations
Health Care

Apellis Pharmaceuticals to Host a Fireside Chat at the Jefferies London Healthcare Conference
WALTHAM, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) today announced that the company will host a fireside chat at the Jefferies London Healthcare Conference on Tuesday, November 19, 2024, at 8:30 a.m. GMT. The live conference webcast will be posted on the "Events and Presentations" page of the "Investors and Media" section of the company's website. A replay of the webcast will be available for approximately 90 days following the event. About ApellisApellis Pharmaceuticals, Inc. is a global biopharmaceutical company that combines courageous science and compassion to develop life-changing therapies for some of the most challenging diseases patients
11/12/24 7:00:00 AM ET
$APLS
Biotechnology: Pharmaceutical Preparations
Health Care
Apellis Pharmaceuticals Reports Third Quarter 2024 Financial Results
Generated $196.8 million in 3Q 2024 revenues, including $176.6 million in U.S. net product salesGrew SYFOVRE® (pegcetacoplan injection) demand by 7% quarter-over-quarter, with U.S. net product revenue of $152.0 million Increase in demand offset by higher gross-to-net adjustments in the quarter Following FDA feedback, on track to file an sNDA seeking approval of pegcetacoplan for C3G / primary IC-MPGN in early 2025 based on positive 6-month Phase 3 VALIANT results Cash and cash equivalents of $396.9 million as of September 30, 2024; projected revenues and cash expected to be sufficient to fund operations to positive cash flow Management to host conference call today at 8:30 a.m. ET
11/5/24 7:05:00 AM ET
$APLS
Biotechnology: Pharmaceutical Preparations
Health Care
Axonis Therapeutics Announces $115 Million Series A Financing
-- Oversubscribed financing brings together leading syndicate of life sciences investors -- -- Proceeds to support clinical development of first-in-class therapies for neurological disorders – BOSTON, Oct. 30, 2024 /PRNewswire/ -- Axonis Therapeutics, a biotechnology company focused on the development of novel neuromedicines, announced today the successful completion of an oversubscribed $115 million Series A financing. Proceeds from the financing will be used to advance Axonis' lead development candidate, AXN-027, through clinical proof-of-concept in patients. AXN-027 is a first-in-class oral small molecule designed to potentiate the function of KCC2, a major CNS chloride transporter essent
10/30/24 6:00:00 AM ET
$AKRO
$APLS
$AUPH
$HRMY
Biotechnology: Pharmaceutical Preparations
Health Care
Specialty Chemicals
Consumer Durables

Apellis Pharmaceuticals And Sobi Announce Positive One-Year Results From Phase 2 NOBLE Study Of Pegcetacoplan For Post-Transplant Recurrence Of C3 Glomerulopathy (C3G) And IC-MPGN

Chat with this insight

Recent Analyst Ratings for $APLS

$APLS Leadership Updates

Live Leadership Updates

Apellis Appoints Leading Expert Dr. Philip Ferrone as Chief Medical Retina Advisor

Apellis Appoints Leading Retina Specialist Dr. Caroline Baumal as Chief Medical Officer

Cognito Therapeutics Appoints Gerald Chan as Chairman of the Board

$APLS Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Morgan Stanley initiated coverage on Apellis Pharmaceuticals with a new price target

RBC Capital Mkts initiated coverage on Apellis Pharmaceuticals with a new price target

Scotiabank initiated coverage on Apellis Pharmaceuticals

$APLS SEC Filings

SEC Form 10-Q filed by Apellis Pharmaceuticals Inc.

SEC Form 8-K filed by Apellis Pharmaceuticals Inc.

SEC Form 10-Q filed by Apellis Pharmaceuticals Inc.

$APLS Financials

Live finance-specific insights

Apellis Pharmaceuticals Reports Third Quarter 2024 Financial Results

Apellis Pharmaceuticals to Host Conference Call on November 5, 2024, to Discuss Third Quarter 2024 Financial Results

Apellis and Sobi Announce Positive Topline Results from Phase 3 VALIANT Study of Pegcetacoplan in C3G and Primary IC-MPGN

$APLS Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Apellis Pharmaceuticals Inc.

Amendment: SEC Form SC 13G/A filed by Apellis Pharmaceuticals Inc.

SEC Form SC 13G/A filed by Apellis Pharmaceuticals Inc. (Amendment)

$APLS FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

$APLS Press Releases

Fastest customizable press release news feed in the world

FDA Approval for EMPAVELI issued to APELLIS PHARMACEUTICALS INC

Apellis Pharmaceuticals to Host a Fireside Chat at the Jefferies London Healthcare Conference

Apellis Pharmaceuticals Reports Third Quarter 2024 Financial Results

Axonis Therapeutics Announces $115 Million Series A Financing

$APLS Market Insights

Live Market Insights

Baird Maintains Outperform on Apellis Pharmaceuticals, Maintains $100 Price Target

Peeling Back The Layers: Exploring Apellis Pharmaceuticals Through Analyst Insights

Goldman Sachs Maintains Buy on Apellis Pharmaceuticals, Lowers Price Target to $77

$APLS Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Executive Officer Francois Cedric disposed of 182,146 shares (SEC Form 4)

General Counsel Watson David O. received a gift of 10,569 shares and gifted 10,569 shares, increasing direct ownership by 10% to 117,721 units (SEC Form 4)

Director Dunlop A. Sinclair exercised 4,600 shares at a strike of $13.19, increasing direct ownership by 3% to 152,126 units (SEC Form 4)

Recent Analyst Ratings for
$APLS

$APLS
Leadership Updates

$APLS
Analyst Ratings

$APLS
SEC Filings

$APLS
Financials

$APLS
Large Ownership Changes

$APLS
FDA approvals

$APLS
Press Releases

$APLS
Market Insights

$APLS
Insider Trading